Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 20, 2015, Pages E2677-E2686

  Hashimoto Kataoka, Takahiro ^a   Hosen, Naoki ^a   Sonobe, Takashi ^b   Arita, Yoh ^a   Yasui, Taku ^a   Masaki, Takeshi ^a   Minami, Masato ^a   Inagaki, Tadakatsu ^b   Miyagawa, Shigeru ^a   Sawa, Yoshiki ^a   Murakami, Masaaki ^a   Kumanogoh, Atsushi ^c   Yamauchi Takihara, Keiko ^a   Okumura, Meinoshin ^a   Kishimoto, Tadamitsu ^d   Komuro, Issei ^e,f   Shirai, Mikiyasu ^b   Sakata, Yasushi ^a   Nakaoka, Yoshikazu ^a,f  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Interleukin 21; Interleukin 6; M2 macrophage; Pulmonary arterial hypertension; Th17 cells

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HELPER CELL; HYPERTENSION; HYPOXIA; IMMUNE RESPONSE; LUNG ALVEOLUS MACROPHAGE; LUNG TRANSPLANTATION; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; POLARIZATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; TH17 CELL; VASCULAR SMOOTH MUSCLE CELL; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; DEFICIENCY; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; METABOLISM; MORPHOMETRY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR REMODELING; WESTERN BLOTTING;

ANIMALIA; MUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHTS AND MEASURES; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; INTERLEUKINS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84929484918     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424774112     Document Type: Article

References (47)

1. Pietra GG, et al. (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(12, Suppl S):25S-32S.
2. Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122(12):4306-4313.
3. Dorfmüller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22(2):358-363.
4. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F (2011) Mechanisms of disease: Pulmonary arterial hypertension. Nat Rev Cardiol 8(8):443-455.
5. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144(2):275-285.
6. Tuder RM, Voelkel NF (1998) Pulmonary hypertension and inflammation. J Lab Clin Med 132(1):16-24.
7. Kishimoto T (2006) Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2):S2.
8. Kishimoto T, Akira S, Taga T (1992) Interleukin-6 and its receptor: A paradigm for cytokines. Science 258(5082):593-597.
9. Humbert M, et al. (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151(5):1628-1631.
10. Soon E, et al. (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122(9):920-927.
11. Steiner MK, et al. (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104(2):236-244.
12. Savale L, et al. (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10:6.
13. Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34(2):149-162.
14. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485-517.
15. Bettelli E, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235-238.
16. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11(10):889-896.
17. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969.
18. Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446):445-455.
19. Vergadi E, et al. (2011) Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123(18):1986-1995.
20. Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52:199-219.
21. Liu SM, King C (2013) IL-21-producing Th cells in immunity and autoimmunity. J Immunol 191(7):3501-3506.
22. Ozaki K, et al. (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298(5598):1630-1634.
23. Takeda Y, et al. (2011) Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479(7371):122-126.
24. Mangan PR, et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441(7090):231-234.
25. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179-189.
26. Choy EH, et al. (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46(12):3143-3150.
27. Nishimoto N, et al. (2004) Treatment of rheumatoid arthritis with humanized antiinterleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50(6):1761-1769.
28. Fujimoto M, et al. (2008) Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 58(12):3710-3719.
29. Iwanami K, et al. (2008) Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 58(3):754-763.
30. Serada S, et al. (2008) IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 105(26):9041-9046.
31. Hsu E, et al. (2011) Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 63(3):783-794.
32. Chaouat A, et al. (2009) Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 136(3):678-687.
33. Daley E, et al. (2008) Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205(2):361-372.
34. Minamino T, et al. (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 98(15):8798-8803.
35. Dienz O, et al. (2009) The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 206(1):69-78.
36. Nurieva R, et al. (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480-483.
37. Korn T, et al. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152):484-487.
38. Zhou L, et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8(9):967-974.
39. Pesce J, et al. (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116(7):2044-2055.
40. Stolfi C, et al. (2011) Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 208(11):2279-2290.
41. Takagi N, et al. (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41(12):2117-2121.
42. Sonobe T, et al. (2011) Imaging of the closed-chest mouse pulmonary circulation using synchrotron radiation microangiography. J Appl Physiol (1985) 111(1):75-80.
43. Higuchi K, et al. (2012) Endothelial Gab1 deletion accelerates angiotensin II-dependent vascular inflammation and atherosclerosis in apolipoprotein E knockout mice. Circ J 76(8):2031-2040.
44. Nakaoka Y, et al. (2007) Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. J Clin Invest 117(7):1771-1781.
45. Ogura S, et al. (2013) Oxidative stress augments pulmonary hypertension in chronically hypoxic mice overexpressing the oxidized LDL receptor. Am J Physiol Heart Circ Physiol 305(2):H155-H162.
46. Arita Y, et al. (2014) Myocardium-derived angiopoietin-1 is essential for coronary vein formation in the developing heart. Nat Commun 5:4552.
47. Shioyama W, et al. (2011) Docking protein Gab1 is an essential component of postnatal angiogenesis after ischemia via HGF/c-met signaling. Circ Res 108(6):664-675.